97 Participants Needed

Mobi-C + Fusion for Cervical Disc Degeneration

Recruiting at 1 trial location
AP
MB
Overseen ByMonica Barascout, BA
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications. However, if you are taking medications that interfere with bone or soft tissue healing, like long-term corticosteroids, you may need to stop them.

What data supports the effectiveness of the treatment Mobi-C for cervical disc degeneration?

Research shows that the Mobi-C implant is effective for treating cervical disc issues, such as spondylosis and radiculopathy, with studies indicating positive outcomes in both single-level and multi-level conditions. Patients have experienced improvements in symptoms and maintained spinal movement over several years.12345

Is the Mobi-C implant safe for humans?

Research shows that the Mobi-C implant is generally safe for humans, with studies indicating no significant differences in adverse events (unwanted side effects) between Mobi-C and other treatments like cervical fusion. However, the quality of adverse event reporting in studies could be improved.13467

How does the Mobi-C treatment differ from other treatments for cervical disc degeneration?

Mobi-C is unique because it is an artificial disc replacement that allows for more natural movement in the spine compared to traditional fusion surgery, which limits motion. This treatment is designed to maintain the range of motion in the neck, potentially reducing stress on adjacent discs and improving overall neck function.12358

What is the purpose of this trial?

The study is a prospective, multi-center cohort study of patients with two-level DDD implanted with CDA adjacent to ACDF (hybrid construct). The overall success of the hybrid procedure will be compared to 2-level ACDF historical controls from the Mobi-C IDE trial. 97 patients will receive the hybrid surgery and will be followed for a minimum of 2 years.

Eligibility Criteria

This trial is for adults aged 22-69 with cervical degenerative disc disease at two levels from C3 to T1, experiencing arm pain or neurological issues with or without neck pain. Candidates must have specific spinal conditions confirmed by CT/MRI, be six weeks into symptom onset or show progressive symptoms despite non-operative treatment, and be able to follow the study protocol and attend follow-up visits within 150 miles of a treatment center.

Inclusion Criteria

I can follow the study plan and fill out necessary forms. I have given or can give my consent.
I live within 150 miles of the treatment center or have approval to participate.
See 3 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Patients undergo hybrid surgery with CDA and ACDF at the same time

6 weeks
In-hospital stay for surgery and initial recovery

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months
Regular follow-up visits for assessments and outcome measures

Long-term Follow-up

Extended monitoring for long-term outcomes and safety

Additional 12 months

Treatment Details

Interventions

  • Mobi-C
Trial Overview The study tests a hybrid surgery combining one level Mobi-C (cervical disc arthroplasty) and one level fusion against historical data from traditional two-level fusion surgeries. It aims to assess the safety and effectiveness of this new approach in treating symptomatic degenerative disc disease over a minimum of two years in 97 patients.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Primary Hybrid ConstructExperimental Treatment1 Intervention
Primary hybrid surgery is when patients undergo CDA and ACDF at the same time.

Find a Clinic Near You

Who Is Running the Clinical Trial?

ZimVie

Lead Sponsor

Trials
27
Recruited
2,400+

Highridge Medical

Lead Sponsor

Trials
1
Recruited
100+

Findings from Research

The Mobi-C implant demonstrated a significantly lower incidence of further surgeries compared to anterior cervical disc fusion (ACDF), with only 1 out of 51 Mobi-C patients requiring re-operation versus 7 out of 48 ACDF patients.
Both Mobi-C and ACDF surgeries effectively improved clinical symptoms in patients with cervical disc degeneration, but the Mobi-C implant allowed for greater range of motion in the treated segment, indicating it may offer functional advantages.
Effectiveness and safety of Mobi-C for treatment of single-level cervical disc spondylosis: a randomised control trial with a minimum of five years of follow-up.Hou, Y., Nie, L., Pan, X., et al.[2022]
The Mobi-C prosthesis was successfully used in 20 patients with degenerative cervical disease, showing no perioperative complications and effective healing of all incisions.
Significant improvements were observed in cervical spinal function and quality of life, with COA scores increasing from 32.10 to 38.20, VAS scores decreasing from 5.10 to 3.20, and NDI scores improving from 39.20 to 29.40 after an average follow-up of 16.5 months.
[Preliminary clinical study on artificial cervical disc replacement by Mobi-C prosthesis].Bao, D., Ma, Y., Chen, X., et al.[2011]
In a study of 42 patients undergoing cervical hybrid surgery with Mobi-C, significant improvements were observed in clinical outcomes such as the modified Japanese Orthopaedic Association (mJOA) score, Neck Disability Index (NDI), and visual analogue scale (VAS) scores post-surgery, indicating the efficacy of the intervention.
While there was some mild to moderate anterior bone loss (ABL) observed in the Mobi-C segments, no severe ABL occurred, and the changes in the flexion-extension center of rotation (FE-COR) did not negatively impact clinical outcomes, suggesting that Mobi-C is a safe option for cervical disc replacement.
Changes in the centre of rotation and the anterior bone loss of the vertebral body in Mobi-C artificial disc replacement segments after cervical hybrid surgery: a retrospective study.Ma, Y., Yu, X., Li, C., et al.[2023]

References

Effectiveness and safety of Mobi-C for treatment of single-level cervical disc spondylosis: a randomised control trial with a minimum of five years of follow-up. [2022]
[Preliminary clinical study on artificial cervical disc replacement by Mobi-C prosthesis]. [2011]
Changes in the centre of rotation and the anterior bone loss of the vertebral body in Mobi-C artificial disc replacement segments after cervical hybrid surgery: a retrospective study. [2023]
[The application of cervical arthroplasty with Mobi-C for treatment of cervical spondylotic radiculopathy]. [2018]
Preliminary Clinical Outcome of One-level Mobi-C Total Disc Replacement in Japanese Population. [2022]
Analysis of segmental cervical spine vertebral motion after prodisc-C cervical disc replacement. [2022]
Adverse events recording and reporting in clinical trials of cervical total disk replacement. [2022]
Comparison of 2-year follow-up results of the hybrid surgery using Mobi-C combined with ROI-C and anterior cervical discectomy and fusion for the treatment of contiguous two-level cervical degenerative disc diseases. [2020]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security